Anticancer effects of four varieties of muscadine grape

Journal of Medicinal Food

Volumn 10, Issue 1, 2007, Pages 54-59

  God, Jason M ^a   Tate, Patricia ^a   Larcom, Lyndon L ^a  

^a CLEMSON UNIVERSITY   (United States)

Author keywords

2 aminoanthracene; Ames assay; Anticarcinogen; Antioxidant; Matrix metalloproteinase; Matrix metalloproteinase 2; Matrix metalloproteinase 9

Indexed keywords

2 AMINOANTHRACENE; CARCINOGEN; GELATINASE A; GELATINASE B; HERBACEOUS AGENT; MESYLIC ACID METHYL ESTER; MUTAGENIC AGENT;

AMES TEST; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARCINOGENESIS; CARLOS; DIXIE; DIXIE RED; DOREEN; ENZYME INHIBITION; GRAPE; MUTAGENESIS; PRIORITY JOURNAL; PURIFICATION;

VITIS ROTUNDIFOLIA;

EID: 34248159368     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.699     Document Type: Article

References (42)

1. American Cancer Society: Cancer Facts and Figures 2005, American Cancer Society, Atlanta, 2005.
2. Slattery ML, Curtin KP, Edwards SL, Schaffer DM: Plant foods, fiber, and rectal cancer. Am J Clin Nutr 2004;79:274-281.
3. Smith-Warner SA, Spiegelman D, Yaun SS, Albanes D, Beeson WL, van den Brandt PA, Feskanich D, Folsom AR, Fraser GE, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Kushi LH, Miller AB, Pietinen P, Rohan TE, Speizer FE, Willett WC, Hunter DJ: Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. Int J Cancer 2003;107:1001-1011.
4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220.
5. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998;92:996-1002.
6. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-1230.
7. Brakenhielm E, Cao R, Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001;15:1798-1800.
8. Shrubsole MJ, Jin F, Dai Q, Shu XO, Potter JD, Hebert JR, Gao YT, Zheng W: Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res 2001; 61:7136-7141.
9. Cohen LA: A review of animal model studies of tomato carotenoids, lycopene, and cancer chemoprevention. Exp Biol Med (Maywood) 2002;227:864-868.
10. Bhat KP, Pezzuto JM: Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 2002;957:210-229.
11. Abdi S, Ali A: Role of ROS modified human DNA in the pathogenesis and etiology of cancer. Cancer Lett 1999;142:1-9.
12. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA: 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G → T and A → C substitutions. J Biol Chem 1992;267: 166-172.
13. Moriya M: Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G.C → T.A transversions in simian kidney cells. Proc Natl Acad Sci U S A 1993;90:1122-1126.
14. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 2000; 21:361-370.
15. Halvorsen BL, Holte K, Myhrstad MC, Barikmo I, Hvattum E, Remberg SF, Wold AB, Haffner K, Baugerod H, Andersen LF, Moskaug O, Jacobs DR, Jr, Blomhoff R: A systematic screening of total antioxidants in dietary plants. J Nutr 2002; 132:461-471.
16. Lein M, Nowak L, Jung K, Laube C, Ulbricht N, Schnorr D, Loening SA: Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. Ann N Y Acad Sci 1999;878: 544-546.
17. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T: Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003;90:1556-1564.
18. Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM: Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003;107:541-550.
19. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, Libert C: Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001;7:1202-1208.
20. D'Armiento J, DiColandrea T, Dalai SS, Okada Y, Huang MT, Conney AH, Chada K: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995;15:5732-5739.
21. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
22. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-5229.
23. Kim TS, Kim YB: Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J Korean Med Sci 1999;14:263-270.
24. Maron DM, Ames BN: Revised methods for the salmonella mutagenicity test. Mutat Res 1983;113:173-215.
25. Ames BN, McCann J, Yamasaki E: Methods for detecting carcinogens and mutagens with Salmonella/Mammalian-Microsome Mutagenicity Test. Mutat Res 1975;31:347-364.
26. Tate P, God J, Bibb R, Lu Q, Larcom LL: Inhibition of metalloproteinase activity by fruit extracts. Cancer Lett 2004;212:153-158.
27. Tate P, Kuzmar A, Smith SW, Wedge DE, Larcom LL: Comparative effects of eight varities of blackberry on mutagenesis. Nutr Res 2003;23:971-979.
28. Beranek DT: Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 1990;231:11-30.
29. Kranendonk M, Mesquita P, Laires A, Vermeulen NPE, Rueff J: Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 1998;13:263-269.
30. Gonzalez FJ, Gelboin HV: Role of human cytochrome P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994;26:165-183.
31. Le Marchand L, Hankin JH, Pierce LM, Sinha R, Nerurkar PV, Franke AA, Wilkens LR, Kolonel LN, Donlon T, Seifried A, Custer LJ, Lum-Jones A, Chang W: Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutat Res 2002;506-507:205-214.
32. Schimmer O, Rauch P: Inhibition of metabolic activation of the promutagens benzópyrene, 2-aminofluorine and 2-aminoanthracene by furanochromes in Salmonella typhimurium. Mutagenesis 1998;13:385-389.
33. Bu-Abbas A, Clifford MN, Walker R, Ioannides C: Marked antimutagenic potential of aqueous green tea extracts: mechanism of action. Mutagenesis, 1994;9:325-331.
34. Ahn D, Putt D, Kresty L, Stoner GD, Fromm D, Hollenberg PF: The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes P450 and phase II enzymes. Carcinogenesis 1996;17:821-828.
35. Kuzuya M, Iguchi A: Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003;10:275-282.
36. Carmeli E, Moas M, Reznick AZ, Coleman R: Matrix metalloproteinases and skeletal muscle: a brief review. Muscle Nerve 2004;29:191-197.
37. Pupa SM, Menard S, Forti S, Tagliabue E: New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259-267.
38. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-650.
39. Liu Z, Ivanoff A, Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 2001;91:638-643.
40. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS: Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002;8:2894-2901.
41. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002;5:1902-1910.
42. Wang TN, Albo D, Tuszynski GP: Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002;132:220-225.